Relay Therapeutics, Inc. (NASDAQ:RLAY) is a top AI-powered biotech stock focusing on oncology by targeting protein dynamics through computational modeling and molecular simulations. Its lead candidate, RLY-2608, is showing promising results in late-stage trials for breast cancer and other rare indications, with analysts projecting a price target nearly four times the current levels. The company is also expanding its pipeline through collaborations with Pfizer and Elevar Therapeutics to accelerate commercialization. While RLAY shows potential for investment, other AI stocks may offer greater upside potential and lower downside risk.

Read more at Yahoo Finance: Relay Therapeutics, Inc. (RLAY) Shows Breakthrough Breast Cancer Results With RLY-2608